AngioDynamics, Inc. (ANGO) analyst actions
Rating and price-target actions on ANGO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ANGO overview →
2 measured ANGO analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia | Press release | +0.50% | -1.50% | |
| AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes | Press release | -1.31% | -1.44% |
Keep exploring
More ANGO: earnings → · SEC filings → · ANGO overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Lipocine Inc. (LPCN) | 219 | +0.34% | 52% |
| Mettler-Toledo International, Inc. (MTD) | 219 | -0.10% | 39% |
| Anixa Biosciences, Inc. (ANIX) | 217 | 0.00% | 49% |
| Entera Bio Ltd. - Ordinary Shares (ENTX) | 217 | 0.00% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.